Drug Trial Radar · NCT06142552
Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
124
Actual
Start
Dec 27, 2023
Primary completion
Oct 8, 2025
Study completion Oct 19, 2025
Sponsor
- Lead sponsor
- Hangzhou Gensciences Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 12 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the prophylactic efficacy of recombinant human coagulation factor Ⅷ-Fc fusion protein (FRSW117) for injection in patients with severe hemophilia A. To evaluate the safety of recombinant human coagulation factor Ⅷ-Fc fusion protein (FRSW117) for injection in patients with severe hemophilia A. Secondary purpose: To evaluate the efficacy of recombinant human coagulation factor Ⅷ-Fc fusion protein for injection (FRSW117) in hemostasis and surgical hemostasis in patients with severe hemophilia A. To evaluate the pharmacokinetic (PK) characteristics of recombinant human coagulation factor Ⅷ-Fc fusion protein (FRSW117) for injection in treated patients with severe hemophilia A. To evaluate the immunogenicity of recombinant human coagulation factor Ⅷ-Fc fusion protein (FRSW117) for injection in treated patients with severe hemophilia A.
Conditions
- Severe Hemophilia A
Interventions
FRSW117Drug
once a week, 50 weeks and as needed
Primary outcomes
What the sponsor says the trial is designed to measure.
- ABRTime frame: 1year
- Effective rate of bleeding treatmentTime frame: 2year
- Safety evaluationTime frame: 3year
- Adverse events/reactionsTime frame: ALL
- Immunogenicity evaluationTime frame: ALL
Locations
28 sites in 1 country. Site status is shown where the registry gives one.
Beijing tongren hospital,CMU
Beijing, China
XiangYa Hospital CentralSouth University
Changsha, China
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, China
Fujian Medical University Union Hospital
Fuzhou, China
Nanfang Hospital of Southern Medical University
Guangzhou, China
The First Affiliated Hospital,Zhejiang University School of Medicine
Hangzhou, China
Anhui Provincial Hospital
Hefei, China
Jinan central hospital
Jinan, China
The First Affiliated Hospital of Shandong First Medical University
Jinan, China
The Second Affiliated Hospital of Kunming Medical University
Kunming, China
The First Hospital of Lanzhou University
Lanzhou, China
Jiangxi Provincial People's Hospital
Nanchang, China
Nanjing Drum Tower Hospital
Nanjing, China
Affiliated Hospital of Nantong University
Nantong, China
The Affiliated Hospital of Qingdao University
Qingdao, China
Ruijin Hospital, Shanghai Jiaotong University School Of Medicine
Shanghai, China
Shenzhen Second People's Hospital
Shenzhen, China
The First Affiliated Hospital of Soochow University
Suzhou, China
The Second Hospital of Shanxi Medical University
Taiyuan, China
North China University of Science and Technology Affiliated Hospital
Tangshan, China
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College
Tianjin, China
Affiliated Hospital of Jiangnan University
Wuxi, China
The First Affiliated Hospital of Xiamen University
Xiamen, China
Zhenyu Li
Xuzhou, China
Subei People's Hospital of Jiangsu province
Yangzhou, China
Henan Cancer Hospital
Zhengzhou, China
Henan Provincial People's Hospital
Zhengzhou, China
Zhengzhou People's Hospital
Zhengzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.